I would take the word withdrawn at face value but not sure if it signals intent on the part of Cytodyn for whatever reason or Bauer, in any event there have to be better drugs to mate with. Regorafenib is hepatotoxic and can cause severe dermatological reactions; dermatological toxicity occurs in over 70% of the patients on the drug. I wouldn’t want Leronlimab guilty by association; it would tarnish an otherwise sterling reputation for safety. Moreover, Leronlimab is already showing anti-angiogenic effect through modulation of VEGF in the tumor micro environment…why throw toxicity into the mix. Maybe Cytodyn has their eyes on a better partner.